<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04592198</url>
  </required_header>
  <id_info>
    <org_study_id>LP-CT-PALO-202002</org_study_id>
    <nct_id>NCT04592198</nct_id>
  </id_info>
  <brief_title>Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting</brief_title>
  <official_title>A Randomized, Dose-ranging, Open-label, Parallel Group Study to Assess the Efficacy, Safety and Pharmacokinetics of Palonosetron HCl Buccal Film Versus IV Palonosetron 0.25 mg (ALOXI®) for the Prevention of Chemotherapy-induced Nausea and</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiamen LP Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiamen LP Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2 study to compare efficacy, safety and PK of palonosetron, a long acting 5-HT3&#xD;
      receptor antagonist, by buccal film delivery compared to iv injection for chemotherapy&#xD;
      induced nausea or vomiting (CINV). Subjects receive a single dose of palonosetron prior to&#xD;
      moderately emetogenic chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2 study to compare efficacy, safety and PK of palonosetron, a long acting&#xD;
      5-HT3 receptor antagonist, by buccal film compared to iv injection for moderately emetogenic&#xD;
      chemotherapy-induced nausea or vomiting (CINV) in cancer patients. Subjects are randomized&#xD;
      into three treatment groups, two with the experimental study drug palonosetron in buccal film&#xD;
      at one of two different doses or the control treatment using Palonosetron hydrochloride iv&#xD;
      injection. Palonosetron PK will be assessed in a subgroup of each treatment group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Actual">March 26, 2021</completion_date>
  <primary_completion_date type="Actual">March 26, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete acute response</measure>
    <time_frame>during the first 24 hours after chemotherapy</time_frame>
    <description>no emetic episode and no rescue medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete delayed response</measure>
    <time_frame>24-120 hours post chemotherapy</time_frame>
    <description>no emetic episode and no rescue medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response</measure>
    <time_frame>up to 120 hours post chemotherapy</time_frame>
    <description>no emetic episode and no rescue medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No nausea</measure>
    <time_frame>up to 120 hours post chemotherapy</time_frame>
    <description>visual analog scale (0-100 mm, 0=no, 100=severe) &lt; 5 mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No significant nausea</measure>
    <time_frame>up to 120 hours post chemotherapy</time_frame>
    <description>visual analog scale (0-100 mm, 0=no, 100=severe) &lt; 25 mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete protection</measure>
    <time_frame>up to 120 hours post chemotherapy</time_frame>
    <description>no emesis, no rescue therapy, no significant nausea (questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of emetic episodes</measure>
    <time_frame>up to 120 hours post chemotherapy</time_frame>
    <description>Number of emetic episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to rescue medication</measure>
    <time_frame>up to 120 hours post chemotherapy</time_frame>
    <description>Time to rescue medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>up to 120 hours post chemotherapy</time_frame>
    <description>time to first emetic episode or administration of rescue therapy, whichever occurred first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of nausea</measure>
    <time_frame>up to 120 hours post chemotherapy</time_frame>
    <description>Rhodes Index of Nausea, Vomiting and Retching (0-4, 0=no nausea, 4=severe nausea)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject global satisfaction with therapy</measure>
    <time_frame>up to 120 hours post chemotherapy</time_frame>
    <description>visual analog scale (0-100mm, 0=not at all satisfied, 100=totally satisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>up to 120 hours post chemotherapy</time_frame>
    <description>Functional Living Index-Emesis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Nausea With Vomiting Chemotherapy-Induced</condition>
  <arm_group>
    <arm_group_label>A (Buccal 0.25 Mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palonosetron HCl Buccal Film 0.25 Mg and oral dexamethasone 12 Mg, both administered on Day 1, and dexamethasone 8 Mg PO on days 2 and 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B (Buccal 0.5 Mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palonosetron HCl Buccal Film 0.5 Mg and oral dexamethasone 12 Mg, both administered on Day 1, and dexamethasone 8 Mg PO on days 2 and 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C (IV Injection 0.25 Mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV palonosetron 0.25 Mg (ALOXI®) and oral dexamethasone 12 Mg, both administered on Day 1, and dexamethasone 8 Mg PO on days 2 and 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron Hydrochloride Buccal Film 0.25 Mg</intervention_name>
    <description>Dose equal to the iv control</description>
    <arm_group_label>A (Buccal 0.25 Mg)</arm_group_label>
    <other_name>Buccal Film Low Dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron Hydrochloride Buccal Film 0.5 Mg</intervention_name>
    <description>Dose twice that of iv control</description>
    <arm_group_label>B (Buccal 0.5 Mg)</arm_group_label>
    <other_name>Buccal Film High dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution</intervention_name>
    <description>iv control</description>
    <arm_group_label>C (IV Injection 0.25 Mg)</arm_group_label>
    <other_name>Control Standard Treatment (Aloxi)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  With histologically or cytologically confirmed malignant disease;&#xD;
&#xD;
               -  Karnofsky index ≥ 50;&#xD;
&#xD;
               -  Be scheduled to receive the first course of MEC to be administered on Day 1&#xD;
&#xD;
          -  Using reliable contraceptive measures;&#xD;
&#xD;
          -  negative serum pregnancy test (if potentially child bearing)&#xD;
&#xD;
          -  Be able to read, understand, and follow the study procedures and able to complete&#xD;
             patient diary autonomously.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Expect to be non-compliant with the study procedures;&#xD;
&#xD;
          -  Received investigational drugs within 30 days before the start of study treatment or&#xD;
             scheduled to receive a highly or moderately emetogenic chemotherapeutic agent during&#xD;
             Day 2 to 6 of the study;&#xD;
&#xD;
          -  Has any condition that could have been associated with a risk of emesis near or at the&#xD;
             time of study drug administration;&#xD;
&#xD;
          -  Have a clinically unstable seizure disorder with seizure activity requiring&#xD;
             anticonvulsant medication;&#xD;
&#xD;
          -  Experienced any vomiting, retching, or National Cancer Institute (NCI) Common Toxicity&#xD;
             Criteria grade 2 or 3 or nausea within 24 hours preceding chemotherapy;&#xD;
&#xD;
          -  Have ongoing nausea or vomiting from any organic etiology;&#xD;
&#xD;
          -  Have severe renal or hepatic impairment;&#xD;
&#xD;
          -  Have positive serology test results;&#xD;
&#xD;
          -  Have a known contraindication to 5-HT3 receptor antagonists;&#xD;
&#xD;
          -  Treated with commercially available or investigative palonosetron formulation within 2&#xD;
             weeks prior to start of study treatment;&#xD;
&#xD;
          -  Allergic to palonosetron or any other 5-HT3 antagonist;&#xD;
&#xD;
          -  Currently a user of any recreational or illicit drugs (including marijuana) or has&#xD;
             current evidence of drug or alcohol abuse or dependence as determined by the&#xD;
             investigator;&#xD;
&#xD;
          -  Will be receiving stem cell rescue therapy in conjunction with study related course of&#xD;
             emetogenic chemotherapy;&#xD;
&#xD;
          -  Received or will receive total body irradiation or radiation therapy to the abdomen or&#xD;
             pelvis in the week prior to Treatment Day 1 and/or during the diary reporting period.&#xD;
&#xD;
          -  Had non-chronic benzodiazepine, opioid or opioid like (e.g., tramadol hydrochloride)&#xD;
             therapy initiated within 48 hours prior to study drug administration or is expected to&#xD;
             receive within 120 hours following initiation of chemotherapy, except for single daily&#xD;
             doses of midazolam, temazepam or triazolam.&#xD;
&#xD;
          -  Started on systemic corticosteroid therapy within 72 hours prior to study drug&#xD;
             administration or is expected to receive a corticosteroid as part of chemotherapy&#xD;
             regimen.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pacific Cancer Medical Center, Inc.</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocala Oncology Center PL DBA Florida Cancer Affiliates</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward H. Kaplan MD &amp; Associates</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic Hematology/Oncology</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gettysburg Cancer Center</name>
      <address>
        <city>Gettysburg</city>
        <state>Pennsylvania</state>
        <zip>17325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monongahela Valley Hospital/ Regional Cancer Center</name>
      <address>
        <city>Monongahela</city>
        <state>Pennsylvania</state>
        <zip>15063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Oncology</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

